Профилактика Гастроинтестинальных Нежелательных Явлений Во Время Терапии 5-Фторурацилом

Кутуков, Владимир Владимирович; Антонян, Виталина Викторовна; Якименко, Ярославна Александровна; Газиев, Марат Алилович

doi:10.46916/30122022-978-5-00174-828-1

Cited by 1 publication

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Пролголимаб получали 40% (n = 12) пациентов, 26,7% (n = 8) -комбинацию «ниволумаб 1 мг/кг + ипилимумаб 3 мг/кг», 23,3% (n = 7) -ниволумаб в монорежиме, 6,7% (n = 2)ипилимумаб, 3,3% (n = 1) -комбинацию «ниволумаб 3 мг/кг + ипилимумаб 1 мг/кг». Медиана наблюдения за пациентами составила девять месяцев [4][5][6][7][8][9][10][11][12][13][14]. Полная клиническая характеристика пациентов представлена в табл.…”

Section: характеристика пациентовunclassified

“…Модуляторы иммунного синапса (анти-CTLA, анти-PD-1/PD-L1) -основные агенты лечения распространенной/рецидивирующей меланомы, демонстрирующие драматическое увеличение общей выживаемости и выживаемости без прогрессирования [4,5]. Учитывая значительное бремя симптомов больных с метастатической меланомой, потенциально высокий риск развития нежелательных явлений при применении ингибиторов контрольных точек, нам представляется необходимым изучение качества жизни таких пациентов [6,7]. Основной источник информации о качестве жизниклинические испытания.…”

Section: Introductionunclassified

See 1 more Smart Citation

Assessment of Quality of Life in Patients with Advanced Melanoma Receiving Immunotherapy with Checkpoint Inhibitors

Sarmatova,

Orlova,

Zhukova

et al. 2023

EPh

View full text Add to dashboard Cite

Objective. To evaluate the quality of life in patients with advanced/recurrent melanoma receiving immunotherapy with checkpoint inhibitors. Material and methods. The study enrolled 30 patients with advanced/recurrent melanoma treated with checkpoint inhibitors in the City Clinical Oncology Center, Saint Petersburg from 2020 to 2023. Quality of life was measured by SF-36 questionnaire and ESAS-R scale thrice: before treatment, after one and three months. Results. The age of the included patients ranged from 30 to 87 years (mean age is 64 ± 11 years, 95% CI 57.20–71.11). Cutaneous melanoma was present in 90% of the patients, while melanoma of mucosal origin was found in 10% of the patients. The functional status of 40% of the patients on the ECOG scale was 2–3 points. 40% (n = 12) of patients received Prolgolimab, 26.7% (n = 8) received the combination of Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg, 23.3% (n = 7) received Nivolumab in mono regimen, 6.7% (n = 2) received Ipilimumab, and 3.3% (n = 1) received the combination Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg. There was a significant decrease in pain (before treatment 2.29 ± 1.979, after 3 months 1.29 ± 1.922 (p = 0.021)), an improvement in the overall symptom profile (before treatment 15.79 ± 11.127, after 1 month – 12.00 ± 8.899, after 3 months – 12.82 ± 12.157 (p = 0.006)) on ESAS-R questionnaire was registered. Improvement was noted in most scales of the SF-36 questionnaire compared with baseline, with statistically significant changes obtained for physical functioning (p = 0.05), pain (p = 0.01), social functioning (p = 0.013), mental health (p = 0.01), overall index of physical health component (p = 0.001), overall index of mental health component (p = 0.042). Conclusion. The results demonstrate a positive effect of treatment with checkpoint inhibitors on the quality of life and symptom profile of patients diagnosed with advanced/recurrent melanoma.

show abstract